- Primary research
- Open Access
Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
© Hurtubise et al; licensee BioMed Central Ltd. 2008
- Received: 16 May 2008
- Accepted: 17 November 2008
- Published: 17 November 2008
Most patients with advanced Ewing's sarcoma (EWS) respond poorly to conventional chemotherapy, indicating the need for new treatment approaches. Epigenetic events, such as promoter hypermethylation and chromatin histone deacetylation, silence the expression of tumor suppressor genes (TSGs) and play an important role in tumorigenesis. These epigenetic changes can be reversed by using 5-aza-2'-deoxycytidine (5AZA-CdR), a potent inhibitor of DNA methylation, in combination with an inhibitor of histone deacetylase (HDAC).
Here, we used a clonogenic assay to evaluate the in vitro antineoplastic activity of 5AZA-CdR in combination with different HDAC inhibitors on EWS cells. We observed that the HDAC inhibitors, MS-275, trichostatin-A, phenylbutyrate, LAQ824 and depsipeptide, enhanced the antineoplastic action of 5AZA-CdR on EWS cells. The combination of 5AZA-CdR and MS-275 showed marked synergy, and was correlated with significant reactivation of the expression of two TSGs, E-cadherin and tumor suppressor lung cancer-1 (TSLC1), in a EWS cell line.
These results suggest the value of future clinical studies investigating the combination of 5AZA-CdR and MS-275 in patients with advanced EWS.
- HDAC Inhibitor
- Clonogenic Assay
- Antineoplastic Action
Metastatic or recurrent Ewing's sarcoma (EWS) does not respond well to standard chemotherapy , suggesting the need for new therapeutic approaches for the treatment of this malignancy. The silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation plays an important role in tumorigenesis . Since this epigenetic change is reversible, it is a potential target for chemotherapeutic intervention. 5-Aza-2'-deoxycytidine (Decitabine, Dacogen, 5AZA-CdR), a potent inhibitor of DNA methylation, has been shown to reactivate the expression of silenced TSGs . 5AZA-CdR has been approved for the treatment of hematological malignancies [4, 5]. However, its antitumor activity is still under investigation. Certain genes that inhibit cellular growth can also be silenced by the deacetylation of chromatin-bound histones, which yields a compact chromatin configuration that is unfavorable for transcription . Histone deacetylase (HDAC) inhibitors can reverse this process to produce an antitumor effect . In addition to reactivation of genes that inhibit tumor growth, HDAC inhibitors can produce cell cycle arrest and induce apoptosis . These inhibitors are currently under clinical investigation in patients with different types of malignancies .
Research has shown that the "cross-talk" between DNA methylation and histone modifications in chromatin can synergistically re-activate TSGs , suggesting that it might be useful to investigate the use of 5AZA-CdR in combination with HDAC inhibitors for tumor therapy. We previously reported that 5AZA-CdR plus depsipeptide (depsi) or phenylbutyrate (PB) showed synergistic antineoplastic action against breast carcinoma cells  and lung carcinoma cells , respectively. We also investigated the ability of 5AZA-CdR and MS-275 to reactivate two TSGs, E-cadherin (ECAD)  and tumor suppressor lung cancer-1 (TSCL1), in EWS cells. Here, we evaluated the in vitro antineoplastic activity of 5AZA-CdR in combination with different HDAC inhibitors: depsi, PB, trichostatin-A (TSA), LAQ824 (LAQ) and MS-275 in EWS cells. Our results revealed that all of the tested HDAC inhibitors enhanced the antineoplastic action of 5AZA-CdR on EWS cells.
5AZA-CdR was obtained from Pharmachemie (Haarlem, Netherlands). Depsi (FR901228) was obtained from Fujisawa Pharmaceutical (Osaka, Japan). LAQ was kindly provided by Novartis Pharmaceuticals Inc. (East Hanover, NJ). TSA was obtained from Wako BioProducts (Richmond, VA). MS-275 was kindly provided by Schering AG (Berlin, Germany). PB was procured from Triple Crown America Inc. (Perkasie, PA). The human TC71 and TC32 EWS cell lines were kindly provided by Dr Jeffrey A. Toretsky (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC). The cells were cultivated as monolayer in RPMI 1640 medium (Life Technologies, Burlington, Ontario) with 10% heat-inactivated fetal calf serum (Wisent, St-Bruno, Quebec) at 37°C with 5% CO2 atmosphere.
The loss of clonogenicity of TC71 and TC32 EWS cell lines was assessed after drug exposure by placing 100–250 cells in each well of a six-well 35 mm dish. The next day different concentrations of 5AZA-CdR and/or HDAC inhibitors: depsi, TSA, PB, MS-275 or LAQ were added at indicated concentrations for 48 h. The cells were washed with drug-free medium and were incubated for an additional 7–11 days and then stained with 0.5% methylene blue in 50% methanol. The colonies (> 500 cells) were counted.
Inhibition of DNA synthesis assay
The inhibition of DNA synthesis by 5AZA-CdR and/or HDAC inhibitors was measured by the incorporation of radioactive thymidine into DNA. Aliquots of ~104cells in 2 ml of medium were placed in each well of a six-well 35 mm dish. The next day, the cells were exposed to the different concentrations of 5AZA-CdR and/or HDAC inhibitors as indicated above. Then, at 48 h, 0.5 μCi of radioactive tritium-labeled thymidine (6.7 Ci/mmol, ICN Biomedicals, Irvine, CA) was added to the medium for an additional 24 h. The cells were then trypsinised, suspended in 0.9% NaCl, placed on a GF/C 25 mm glass fiber filter disc, washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters were dried, placed in EcoLite scintillation fluid (ICN Biomedicals) and the radioactivity was measured with a scintillation counter.
Isolation of RNA and RT-PCR analysis
In order to study the reactivation of gene in EWS cell lines, we treated cells with 5AZA-CdR (100 ng/ml) and/or MS-275 (250 ng/ml) for 72 h. Cells were harvested 24 h after the removal of the drugs and total RNA was isolated using RNeasy Mini Kit (Qiagen, Mississauga, Ontario). For cDNA synthesis, total RNA was reverse-transcribed using OmniScript RT kit (Qiagen). The reaction was performed at 37°C for 1 h followed by 5 min at 93°C to inactivate the enzyme. PCR amplifications were performed using HotStar Taq Polymerase (Qiagen) and specific primers spanning different exons for ECAD, TSLC1 and 18S ribosomal RNA. For ECAD (GenBank NM_004360), the primers were sense 5'-CAATCCCACC ACGTACAAG-3' and antisense 5'-CTGGGCAGTGTAGGATGTGA-3'. The length of the PCR product of ECAD was 410 bp. For TSLC1 (GenBankNM_014333), the primers were sense 5'-GGGCAGAATCTGTTTA CGAAAGA-3' and antisense 5'-TCGGTATAGAGCTGGCAAAAGTA-3'. The length of the PCR product of TSLC1 was 257 bp. The human 18S ribosomal RNA gene (GenBank X03205) was amplified as an internal control using as sense primer 5'-TCGATGGTAG TCGCCGTGCCTA-3' and antisense 5'-CTGCTGCCTTCCTTGGATGTGGTA-3'. The length of the PCR product of 18S ribosomal RNA was 110 bp. Samples were amplified in a thermocycler under the following conditions. For ECAD, the PCR conditions were 5 min at 95°C, 15 s at 94°C, 15 s at 58°C and 15 s at 72°C, for 5 cycles. Then, the annealing temperature was lowered at 56°C for 35 more cycles. For TSLC1, the PCR conditions were 5 min at 95°C, 30 s at 94°C, 15 s at 56°C and 15 s at 72°C, for 5 cycles. Then, the annealing temperature was lowered at 54°C for 34 more cycles. For 18S ribosomal RNA, the PCR conditions were 5 min at 95°C, 45 s at 94°C, 30 s at 60°C and 30 s at 72°C, for 5 cycles. Then, the annealing temperature was lowered at 58°C for 11 more cycles. For each gene, the number of cycle chosen as to be in the exponential phase of DNA amplification. The PCR products were electrophoresed on 2% agarose gel and detected by ethidium bromide staining. The measurement of the absolute concentration of amplified DNA was obtained with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) as described previously. This latter method, which is very sensitive, uses capillary electrophoresis and fluorescent detection to measure both the size and quantity of DNA.
The data are the mean values ± SD for n ≥ 3. Differences between groups were analyzed using one-way ANOVA test coupled with a Tukey-Kramer test, by comparing the result of each drug alone with the results of the combination of both agents. The critical level of significance was set at p ≤ 0.05.
There is an urgent need to develop new approaches for the chemotherapy of advanced EWS. The inhibitor of DNA methylation, 5AZA-CdR, is an interesting agent to investigate for tumor therapy, since it can reactivate silenced TSGs . This epigenetic agent has proven effective in patients with hematological malignancies [4, 5], and has shown some promising activity in patients with advanced lung cancer . The HDAC inhibitors are another class of epigenetic agents that are of interest in the context of cancer therapy. These inhibitors convert chromatin to an open, transcription-facilitating conformation , and have been shown to have diverse actions on tumor cells, including activation of growth-inhibiting genes, induction of apoptosis, inhibition of cell cycle progression, and inhibition of human tumor xenografts in nude mice [8, 17, 18]. Several HDAC inhibitors are currently under clinical investigation in patients with solid tumors .
In this study, we first evaluated the single-agent antineoplastic action of 5AZA-CdR and five different HDAC inhibitors on human TC71 and TC32 EWS cell lines. In assays on loss of clonogenicity and inhibition of DNA synthesis, we observed good dose-response curves with 5AZA-CdR and all of the HDAC inhibitors. Both classes of epigenetic agents showed potential as single agents for the treatment of EWS.
Since a landmark study showed that an inhibitor of DNA methylation in combination with an HDAC inhibitor produced a synergistic reactivation of TSGs in neoplastic cells , we next investigated whether 5AZA-CdR in combination with HDAC inhibitors produces an additive or synergistic antineoplastic effect on EWS cells. In the clonogenic assay, we observed that 5AZA-CdR in combination with different HDAC inhibitors (TSA, LAQ, PB, Depsi and MS-275) produced an additive or synergistic antineoplastic interaction against TC71 EWS cells. We previously reported a synergistic antineoplastic interaction between 5AZA-CdR and some of these HDAC inhibitors for breast and lung tumor cell lines [11, 12].
In particular, the combination of 5AZA-CdR and MS-275 showed a marked synergistic interaction with respect to antineoplastic activity against EWS cells. This combination also produced a synergistic reactivation of two TSGs: ECAD and TSLC1. A previous report showed that MS-275 has significant in vitro and in vivo antitumor activity against EWS [17, 18], and MS-275 showed promising results in a phase I study on patients with EWS . These previous findings and our present results combine to suggest that 5AZA-CdR and MS-275 may be a good combination of epigenetic agents to investigate in patients with advanced EWS.
This study was supported by a grant from the Canadian Cancer Society (RLM #014193). AH is supported by a studentship from the Fonds de la recherche en santé du Québec.
- Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H: Ewing's sarcoma family of tumors: current management. Oncologist. 2006, 11: 503-519. 10.1634/theoncologist.11-5-503.View ArticlePubMedGoogle Scholar
- Jones PA, Baylin S: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-28. 10.1038/nrg962.View ArticlePubMedGoogle Scholar
- Momparler RL: Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). Semin Hematol. 2005, 42: S9-16. 10.1053/j.seminhematol.2005.05.002.View ArticlePubMedGoogle Scholar
- Issa JP, Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004, 103: 1635-1640. 10.1182/blood-2003-03-0687.View ArticlePubMedGoogle Scholar
- Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol. 2001, 114: 349-357. 10.1046/j.1365-2141.2001.02933.x.View ArticlePubMedGoogle Scholar
- Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer. 2001, 1: 194-202. 10.1038/35106079.View ArticlePubMedGoogle Scholar
- Conley BA, Wright JJ, Kummar S: Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer. 2006, 107: 832-840. 10.1002/cncr.22064.View ArticlePubMedGoogle Scholar
- Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003, 63: 4460-4471.PubMedGoogle Scholar
- Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005, 45: 495-528. 10.1146/annurev.pharmtox.45.120403.095825.View ArticlePubMedGoogle Scholar
- Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999, 21: 103-107. 10.1038/5047.View ArticlePubMedGoogle Scholar
- Primeau M, Gagnon J, Momparler RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Intl J Cancer. 2003, 103: 177-184. 10.1002/ijc.10789.View ArticleGoogle Scholar
- Boivin A-J, Momparler LF, Hurtubise A, Momparler RL: Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anti-Cancer Drugs. 2002, 13: 869-874. 10.1097/00001813-200209000-00013.View ArticlePubMedGoogle Scholar
- Nam JS, Ino Y, Kanai Y, Sakamoto M, Hirohashi S: 5-aza-2'-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis. Clin Exp Metastasis. 2004, 21: 49-56. 10.1023/B:CLIN.0000017180.19881.c1.View ArticlePubMedGoogle Scholar
- Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP: Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 2003, 38: 170-178. 10.1002/mc.10156.View ArticlePubMedGoogle Scholar
- Valeriote F, Lin H: Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep. 1975, 59: 895-900.PubMedGoogle Scholar
- Momparler RL, Ayoub J: Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer. 2001, 34: S111-115. 10.1016/S0169-5002(01)00397-X.View ArticlePubMedGoogle Scholar
- Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002, 62: 6108-6015.PubMedGoogle Scholar
- Eyüpoglu IY, Hahnen E, Tränkle C, Savaskan NE, Siebzehnrübl FA, Buslei R, Lemke D, Wick W, Fahlbusch R, Blümcke I: Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther. 2006, 5: 1248-1255. 10.1158/1535-7163.MCT-05-0533.View ArticlePubMedGoogle Scholar
- Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ: Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res. 2007, 13: 5411-5417. 10.1158/1078-0432.CCR-07-0791.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.